162P Efficacy and safety of GEMOX (gemcitabine plus oxaliplatin) plus sintilimab and bevacizumab as a conversion therapy in patients with initially unresectable biliary tract cancers (BTC): A single-arm, phase II study. (December 2022)

Record Type:: Journal Article
Title:: 162P Efficacy and safety of GEMOX (gemcitabine plus oxaliplatin) plus sintilimab and bevacizumab as a conversion therapy in patients with initially unresectable biliary tract cancers (BTC): A single-arm, phase II study. (December 2022)
Main Title:: 162P Efficacy and safety of GEMOX (gemcitabine plus oxaliplatin) plus sintilimab and bevacizumab as a conversion therapy in patients with initially unresectable biliary tract cancers (BTC): A single-arm, phase II study
Authors:: Zhang, N.
Zhou, J.
Wang, L.
Zhang, T.
Zhu, W.
Mao, A.
Pan, Q.
Lin, Z.
Wang, M.
Zhang, Y.
Feng, Y.
Xu, W.
Zhao, Y.
Wang, L.
Abstract:
Is Part Of:: Immuno-oncology technology. Volume 16(2022)Supplement 1
Journal:: Immuno-oncology technology
Issue:: Volume 16(2022)Supplement 1
Issue Display:: Volume 16, Issue 1 (2022)
Year:: 2022
Volume:: 16
Issue:: 1
Issue Sort Value:: 2022-0016-0001-0000
Page Start:
Page End:
Publication Date:: 2022-12
Subjects:: Cancer -- Immunotherapy -- Periodicals
616.994061
Journal URLs:: https://www.esmoiotech.org/issues ↗
http://www.sciencedirect.com/ ↗
DOI:: 10.1016/j.iotech.2022.100274 ↗
Languages:: English
ISSNs:: 2590-0188
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 24744.xml